{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:41:50Z","timestamp":1759693310875,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2007]]},"DOI":"10.1016\/j.mehy.2006.05.070","type":"journal-article","created":{"date-parts":[[2006,10,3]],"date-time":"2006-10-03T08:04:53Z","timestamp":1159862693000},"page":"565-567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Revival of nifedipine, a dihydropyridine-based calcium blocker"],"prefix":"10.1016","volume":"68","author":[{"given":"S.","family":"Yamagishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2006.05.070_bib1","doi-asserted-by":"crossref","first-page":"4S","DOI":"10.1016\/S0895-7061(03)00969-5","article-title":"The burden of cardiovascular disease: following the link from hypertension to myocardial infarction and heart failure","volume":"9","author":"Black","year":"2003","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.mehy.2006.05.070_bib2","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1097\/00004872-200306000-00002","article-title":"Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003","volume":"21","author":"Staessen","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.mehy.2006.05.070_bib3","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials","volume":"362","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2006.05.070_bib4","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11906-001-0097-4","article-title":"Prospectively designed overviews of recent trials comparing antihypertensive regimens based on different drug classes","volume":"3","author":"Chapman","year":"2001","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.mehy.2006.05.070_bib5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1161\/01.HYP.0000184541.24700.c7","article-title":"Calcium antagonists. Effects on cardio-renal risk in hypertensive patients","volume":"46","author":"Nathan","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.mehy.2006.05.070_bib6","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1046\/j.1523-1755.1998.00912.x","article-title":"Antihypertensive treatment of patients with proteinuric renal disease: risks or benefits of calcium channel blockers?","volume":"53","author":"Kloke","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.mehy.2006.05.070_bib7","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1523-1755.2004.00620.x","article-title":"Different effects of calcium antagonist subclasses on markers of nephropathy progression","volume":"65","author":"Bakris","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.mehy.2006.05.070_bib8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1524-6175.2006.05335.x","article-title":"Physician familiarity with diagnosis and management of hypertension according to JNC 7 guidelines","volume":"8","author":"Sisson","year":"2006","journal-title":"Clin Hypertens"},{"key":"10.1016\/j.mehy.2006.05.070_bib9","doi-asserted-by":"crossref","unstructured":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: p. 1\u2013290.","DOI":"10.1053\/j.ajkd.2004.03.003"},{"key":"10.1016\/j.mehy.2006.05.070_bib10","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(04)16980-8","article-title":"Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial","volume":"364","author":"Poole-Wilson","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2006.05.070_bib11","doi-asserted-by":"crossref","first-page":"H1813","DOI":"10.1152\/ajpheart.00036.2004","article-title":"In vivo TNF-alpha inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure","volume":"287","author":"Moe","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.mehy.2006.05.070_bib12","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1161\/01.CIR.0000055318.09997.1F","article-title":"Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes","volume":"107","author":"Suematsu","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.mehy.2006.05.070_bib13","first-page":"141","article-title":"Nifedipine inhibits apoptotic cell death of cultured endothelial cells induced by tumor necrosis factor-alpha","volume":"29","author":"Yamagishi","year":"2003","journal-title":"Drugs Exp Clin Res"},{"key":"10.1016\/j.mehy.2006.05.070_bib14","first-page":"147","article-title":"Nifedipine inhibits tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH oxidase-mediated reactive oxygen species generation","volume":"29","author":"Yamagishi","year":"2003","journal-title":"Drugs Exp Clin Res"},{"key":"10.1016\/j.mehy.2006.05.070_bib15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0168-8227(01)00288-1","article-title":"J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics","volume":"54","author":"Baba","year":"2001","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.mehy.2006.05.070_bib16","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0008-6363(97)00233-2","article-title":"AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept","volume":"37","author":"Bierhaus","year":"1998","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.mehy.2006.05.070_bib17","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s11883-000-0082-4","article-title":"Atherosclerosis and diabetes: the RAGE connection","volume":"2","author":"Schmidt","year":"2000","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.mehy.2006.05.070_bib18","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.2174\/1381612054367300","article-title":"Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy","volume":"11","author":"Yamagishi","year":"2005","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.mehy.2006.05.070_bib19","first-page":"169","article-title":"Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation","volume":"30","author":"Yamagishi","year":"2004","journal-title":"Drugs Exp Clin Res"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987706006086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987706006086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:12:27Z","timestamp":1759691547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987706006086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007]]}},"alternative-id":["S0306987706006086"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2006.05.070","relation":{},"ISSN":["0306-9877"],"issn-type":[{"type":"print","value":"0306-9877"}],"subject":[],"published":{"date-parts":[[2007]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revival of nifedipine, a dihydropyridine-based calcium blocker","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2006.05.070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}